Abstract
Abstract Purpose In 2015, an interdisciplinary project was started to fill the gap of knowledge on the toxicokinetics of aluminium (Al) after exposure from adjuvanted products for subcutaneous immunotherapy (SCIT). Methods Two complementary initiatives of the project are explained. The results of two studies are reviewed and put in connection with the overarching goal. An estimate is given which steps have been reached and which are still needed. Results Recent in vivo data provided evidence of systemically available Al from SCIT products in rats (Weisser et al. 2020 [1]). The data are highly valuable for further development of the physiology-based toxicokinetic (PBTK) model for Al exposure which has been established in parallel (Hethey et al. 2021 [2]). Conclusion The Hethey model is an important step towards prediction of Al exposure in man from various sources. For use in risk assessment of Al exposure from SCIT products further extension of the model is warranted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
